touchCLINICAL PERSPECTIVES

Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies

Access to this content is not permitted for healthcare professionals based in the UK

Back to Education
touchNEUROLOGY touchNEUROLOGY
Play ArrowPlay Video
Play ArrowPlay Video
Play ArrowPlay Video
Play ArrowPlay Video
Play ArrowPlay Video
Play ArrowPlay Video

touchCLINICAL PERSPECTIVES
A modular programme that includes a variety of interviews with experts and a patient, as well as downloadable resources. Close

Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies

Addressing the burden of migraine: The role of anti-CGRP antibodies in practice

After watching this activity, participants should be better able to:

  • Explain the impact of migraine on patient quality of life and the importance of prevention

Recognizing the burden of migraine in daily life

After watching this activity, participants should be better able to:

  • Explain the impact of migraine on patient quality of life and the importance of prevention

Anti-CGRP antibodies for migraine prevention: Insights from real-world evidence

After watching this activity, participants should be better able to:

  • Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention

Treatment failure in patients with migraine: Insights and guidance

After watching this activity, participants should be better able to:

  • Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention
  • Formulate a strategy for stopping and restarting anti-CGRP antibodies for migraine prevention

Anti-CGRP antibodies for patients with migraine: Practical management

After watching this activity, participants should be better able to:

  • Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention
  • Formulate a strategy for stopping and restarting anti-CGRP antibodies for migraine prevention

Using anti-CGRP antibodies for migraine prevention: Key learnings

After watching this activity, participants should be better able to:

  • Explain the impact of migraine on patient quality of life and the importance of prevention
  • Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention
  • Formulate a strategy for stopping and restarting anti-CGRP antibodies for migraine prevention

Topics covered in this activity

Headache Disorders
REGISTER NOW FOR FREE ACCESS TO
  • 1000+ topical and insightful peer-reviewed journal articles
  • 1000+ topical and insightful peer-reviewed journal articles
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
Claim Credit
touchCLINICAL PERSPECTIVES
Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32 social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72